Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

Table 1

Baseline demographic data.

Malignant pleural mesothelioma ()	245 patients
Age, median (range), y	68 (21 to 88)
Gender, number (%)
Men	213 (86.9%)
Women	32 (13.1%)
Known asbestos, number (%)
Yes	123 (50.2%)
No	122 (49.8%)
Eastern Cooperative Oncology Group (ECOG) performance status, number (%)
0	37 (15.1%)
1	117 (47.8%)
2	51 (20.8%)
3	19 (7.8%)
4	2 (0.8%)
Unknown	19 (7.8%)
Initial staging, number (%)
I	84 (34.3%)
II	20 (8.2%)
III	69 (28.2%)
IV	63 (25.7%)
Unknown	9 (3.7%)
Histology, number (%)
Epithelial	154 (62.9%)
Sarcomatoid	34 (13.9%)
Mixed	27 (11%)
Unknown	30 (12.2%)
Laterality, number (%)
Left	97 (39.6%)
Right	138 (56.3%)
Bilateral	5 (2%)
Unknown	5 (2%)
Presenting symptoms and signs, number (%)
Dyspnea	186 (75.9%)
Pleural effusion	179 (73.1%)
Chest pain	118 (48.2%)
Weight loss (≥5%)	89 (36.3%)
Cough	71 (29%)
Dysphagia	7 (2.9%)
Pericardial effusion	5 (2%)